• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing

byMinjee Kim
September 16, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Topical application of ON101, a macrophage regulator cream, demonstrated superior therapeutic efficacy in the treatment of diabetic foot ulcers compared to standard absorbent dressing in terms of both complete healing rate and time to complete healing.

2. Therapeutic efficacy of ON101 was sustained in patients with high-risk factors including ulcers that last for more than 6 months, measure greater than 5 cm2, or in patients with high HbA1c levels.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Diabetic foot ulcers (DFUs) are a common complication of chronic diabetes. Current standard treatments focus mainly on local wound care, including debridement, off-loading, infection control, and maintaining a moist environment with dressings, along with adequate glycemic control systemically. Newer drugs focus on restoring the balance between M1/M2-type macrophages that are known to play a critical role in wound healing and frequently dysregulated in patients with delayed healing of DFUs. However, these drugs have not yet been studied in large randomized clinical trials. This multicenter, phase 3 randomized clinical trial sought to evaluate whether topical application of ON101, a macrophage regulator cream, could treat chronic DFUs by comparing it with a standard primary wound care absorbent dressing. The main endpoint of the analysis was the incidence of complete wound healing, defined as complete re-epithelialization at 2 consecutive visits during the 16-week treatment period. Furthermore, data on safety outcomes was collected including the incidences of adverse events, clinical laboratory values, and vital signs. Among 236 patients with DFUs, topical application of ON101 cream post-debridement demonstrated significantly improved wound healing efficacy compared to standard practice using absorbent dressing, including in patients with DFU-related risk factors. These findings suggested that ON101, a cream that regulates M1:M2 macrophage ratio, demonstrated superior therapeutic efficacy in the treatment of DFUs compared to standard absorbent dressing in terms of both complete healing rate and time to complete healing. Additionally, therapeutic efficacy of ON101 was sustained in patients with high-risk factors including ulcers that last for more than 6 months, measure greater than 5 cm2, or in patients with high HbA1c levels. These results suggested that topical application of ON101 represented an active wound healing alternative for primary care of patients with chronic DFUs. A limitation of this study was the lack of masking of the interventions to patients or clinical investigators due to the open-label design of the study, introducing possible biases from the blinded evaluation.

Click to read the study in JAMA Network Open

Relevant Reading: Current challenges and opportunities in the prevention and management of diabetic foot ulcers

In-Depth [randomized controlled trial]: This multicenter, evaluator-blinded, phase 3 randomized clinical trial enrolled 236 patients (175 men [74.2%]; mean [SD] age, 57.0 [10.9] years; mean [SD] glycated hemoglobin level, 8.1% [1.6%]) from 21 centers across the US, China, and Taiwan between November 2012 and May 2020. Eligible patients had DFUs between 1 to 25 cm2 (mean [SD] ulcer area, 4.8 [4.4] cm2) present for at least 4 weeks classified as Wagner grade 1 or 2 and were randomized 1:1 to receive either ON101 cream (n = 122) or absorbent dressing (n = 114) for as long as 16 weeks, with a 12-week follow-up. Overall, complete wound healing was observed in 74 (60.7%) and 40 (35.1%) patients in the ON101 and dressing comparator cohorts respectively during the 16-week treatment period (difference, 25.6%; OR, 2.84; 95%CI, 1.66-4.84; P < .001). Treatment-emergent adverse events occurred in 7 (5.7%) patients in the ON101 cohort vs 5 (4.4%) in the comparator cohort. Lastly, no treatment-related serious adverse events were observed in the ON101 cohort vs 1 (0.9%) in the comparator cohort.

RELATED REPORTS

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #DFUs#DM#foot ulceration#M1/M2 macrophages#macrophage#ON101diabetesdiabetes mellitusdiabetic foot ulcersFoot Ulcers
Previous Post

Heterologous ChAdOx1 prime-boosted vaccination schedules are non-inferior to homologous vaccination

Next Post

Wellness Check: Sleep

RelatedReports

Classics Series, Landmark Trials in Medicine
Emergency Classics

The ACCORD trial: Intensive glucose control associated with increased mortality [Classics Series]

May 4, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Chronic Disease

Associations of dietary patterns and lifestyle modifications with glycemic control in diabetic patients

April 29, 2022
Filtered-sunlight may effectively treat neonatal jaundice in resource-poor settings
Cardiology

Light exposure during sleep may alter glucose metabolism and impair cardiometabolic function

April 19, 2022
Next Post
Plagiocephaly/brachycephaly associated with lower cognitive and academic achievement scores

Wellness Check: Sleep

#VisualAbstract: Tumor primary site may be a prognostic factor for patients with Merkel cell carcinoma

#VisualAbstract: Post-induction chemotherapy Epstein-Barr virus DNA is an effective prognostic indicator for nasopharyngeal carcinomas

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Detection of pathogenic genetic variants in early-onset atrial fibrillation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.